Insider Hedge: Crinetics CCO Sells at Premium While Exercising Huge Option Tranche to Bet on Future Breakthroughs
Crinetics insider trading shows bullish confidence: CCO Kalofonos buys and sells shares, exercises options, boosting long‑term commitment amid a $350 m IPO, signaling growth potential in oncology and endocrine pipelines.
- Crinetics Pharmaceuticals Inc
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read